BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Displays CDMO Expertise at Prestigious Biomed Israel Conference
- Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment
- BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services
- The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which drew over 6,000 attendees from a wide variety of international life sciences disciplines
- BiondVax’s NanoAb drug candidate pipeline has expanded focus on immune system cytokine targets for treating psoriasis and psoriatic arthritis
Israel-based biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV) is building on positive preclinical data regarding its innovative inhaled anti-SARS-CoV-2 nanosized antibody (NanoAb) product with plans to develop further NanoAbs targeting immune system cytokines while the company expands its frontiers by beginning to offer contract development and manufacturing organization (“CDMO”) services.
BiondVax showcased its CDMO services and expertise at the premier conference for international Life Science and HealthTech industries earlier this month in Israel. The 21st annual Biomed Israel drew more than 6,000 industry leaders, scientists, engineers, physicians, and investors from over 45 countries, providing BiondVax a worldwide stage for exhibiting its potential blockbuster products and state-of-the-art assets and services.
“Senior executives and delegations from multinationals, big pharma, medical devices, tech giants and international investors in the health industry come to Israel each May to ‘shop for’ innovation in the field, in search of creative solutions, products and technologies, and the next big thing,” Biomed Israel Co-chairwoman Ruti Alon stated in a news release about the event (https://nnw.fm/0Wua5 ).
BiondVax has gained significant expertise in developing and producing current good manufacturing practice (“cGMP”) compliant drug candidates, working from preclinical stage to Phase 3 clinical trials. Making its cGMP manufacturing facility available for the development of other companies’ products helps to advance the potential of improving medical therapies and responding to unmet medical needs.
The company’s CDMO services include aseptic filling, upstream and downstream process development, as well as analytical model development. BiondVax is contracting its suite of boutique end-to-end services (https://nnw.fm/Oggrv ) to large pharmaceutical and biotech companies, alternative protein food tech companies, and smaller development-stage companies in general.
Offering CDMO services “allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” CEO Amir Reichman stated in a year-end letter to shareholders (https://nnw.fm/mxQq0 ).
“The team already knows how to work together. The team has experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — everything works; it’s an oiled machine. Also the capacity and the capabilities are there,” Reichman said in a March interview with Digital Niche Agency that addressed BiondVax’s efforts to strengthen its value for its shareholders (https://nnw.fm/DkUhZ ).
A recent statement on the company’s quarterly financial results noted that the company has begun R&D activities for the innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis, both large market disorders with large unmet medical needs.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment
- BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services
- The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which drew over 6,000 attendees from a wide variety of international life sciences disciplines
- BiondVax’s NanoAb drug candidate pipeline has expanded focus on immune system cytokine targets for treating psoriasis and psoriatic arthritis
Israel-based biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV) is building on positive preclinical data regarding its innovative inhaled anti-SARS-CoV-2 nanosized antibody (NanoAb) product with plans to develop further NanoAbs targeting immune system cytokines while the company expands its frontiers by beginning to offer contract development and manufacturing organization (“CDMO”) services.
BiondVax showcased its CDMO services and expertise at the premier conference for international Life Science and HealthTech industries earlier this month in Israel. The 21st annual Biomed Israel drew more than 6,000 industry leaders, scientists, engineers, physicians, and investors from over 45 countries, providing BiondVax a worldwide stage for exhibiting its potential blockbuster products and state-of-the-art assets and services.
“Senior executives and delegations from multinationals, big pharma, medical devices, tech giants and international investors in the health industry come to Israel each May to ‘shop for’ innovation in the field, in search of creative solutions, products and technologies, and the next big thing,” Biomed Israel Co-chairwoman Ruti Alon stated in a news release about the event (https://nnw.fm/0Wua5 ).
BiondVax has gained significant expertise in developing and producing current good manufacturing practice (“cGMP”) compliant drug candidates, working from preclinical stage to Phase 3 clinical trials. Making its cGMP manufacturing facility available for the development of other companies’ products helps to advance the potential of improving medical therapies and responding to unmet medical needs.
The company’s CDMO services include aseptic filling, upstream and downstream process development, as well as analytical model development. BiondVax is contracting its suite of boutique end-to-end services (https://nnw.fm/Oggrv ) to large pharmaceutical and biotech companies, alternative protein food tech companies, and smaller development-stage companies in general.
Offering CDMO services “allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” CEO Amir Reichman stated in a year-end letter to shareholders (https://nnw.fm/mxQq0 ).
“The team already knows how to work together. The team has experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — everything works; it’s an oiled machine. Also the capacity and the capabilities are there,” Reichman said in a March interview with Digital Niche Agency that addressed BiondVax’s efforts to strengthen its value for its shareholders (https://nnw.fm/DkUhZ ).
A recent statement on the company’s quarterly financial results noted that the company has begun R&D activities for the innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis, both large market disorders with large unmet medical needs.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
